ArticleJTO clinical and research reports2025

Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response.

Iris van 't Erve et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.